Letrozole vs Anastrozole: Key Facts and Differences

Letrozole and anastrozole are both aromatase inhibitors used primarily to treat hormone receptor-positive breast cancer in postmenopausal women, and in head-to-head trials they produce nearly identical outcomes in disease-free survival and overall tolerability. Letrozole is measurably more potent at suppressing estrogen, but that pharmacological edge has not translated into a clear survival advantage. The practical differences between the two show up in subtler places: how the body processes each drug, how they interact with other medications, and where each one has carved out off-label territory.

How They Block Estrogen

Both drugs work by disabling aromatase, the enzyme responsible for converting androgens into estrogen. In postmenopausal women, the ovaries have stopped producing estrogen directly, so aromatase activity in fat tissue, muscle, and the tumor itself becomes the primary source. By shutting down that enzyme, both letrozole and anastrozole starve hormone-sensitive breast cancer cells of the estrogen they need to grow.

Where they diverge is in how completely they do the job. In lab assays, letrozole is roughly 10 to 20 times more potent than anastrozole at inhibiting aromatase in cellular systems.¹ That gap narrows considerably in the human body, but it does not disappear. A randomized crossover study in which the same patients received both drugs found that aromatase activity was undetectable in all 12 patients during letrozole treatment (more than 99.1% suppression), while it remained measurable in 11 of 12 patients on anastrozole (about 97.3% suppression).² Letrozole also drove plasma estrogen levels lower. Reanalyzed plasma samples showed letrozole suppressed estradiol by about 95% versus roughly 93% with anastrozole, and the differences in estrone and estrone sulfate were even wider.³

These percentage differences sound small, but at already-low postmenopausal estrogen levels, even a few percentage points can represent a meaningful absolute change in circulating hormone. Whether that matters clinically is a question the efficacy trials address.

Pharmacokinetic Differences

Letrozole lingers in the body longer than anastrozole. Anastrozole’s half-life runs around 41 to 48 hours, while letrozole’s half-life can stretch to two to four days.⁴ Both reach steady-state blood levels within about a week of daily dosing, though some data suggest letrozole can take considerably longer to reach full steady-state, up to around 60 days.

Their metabolism pathways also diverge. Anastrozole mainly inhibits the liver enzymes CYP1A2 and CYP2C8/9, with some effect on CYP3A4. Letrozole acts more strongly on CYP2A6 and has moderate effects on CYP2C19.⁴ In plain terms, the two drugs interact with different sets of liver enzymes, which means each one has its own profile of potential drug interactions. If you are taking other medications metabolized through specific liver pathways, one drug could be a better fit than the other. This is the kind of detail your oncologist factors in when choosing between them.

Does the Potency Gap Change Outcomes?

The most direct comparison comes from the FACE trial, a large randomized study that enrolled over 4,000 postmenopausal women with hormone receptor-positive, node-positive early breast cancer. After years of follow-up, the five-year disease-free survival rate was about 85% with letrozole and 83% with anastrozole. That small numerical difference was not statistically significant, and exploratory analyses showed similar results across every subgroup examined.⁵

A neoadjuvant study that compared letrozole, anastrozole, and exemestane (the third aromatase inhibitor) in women treated before surgery also found no meaningful differences in surgical outcomes or tumor biomarker suppression between the three drugs.⁶ A 2025 study looking at real-world outcomes across all three aromatase inhibitors found that anastrozole and letrozole had nearly identical five-year treatment discontinuation rates, around 35%, compared with about 39% for exemestane.⁷

The bottom line for breast cancer treatment is that letrozole’s stronger estrogen suppression has not produced a detectable survival advantage over anastrozole in major trials. Oncologists generally treat them as interchangeable for this purpose, choosing based on side-effect profiles, drug interactions, and patient preference.

Side Effects and Tolerability

Because both drugs suppress estrogen by the same fundamental mechanism, they share the same core side effects: joint pain and stiffness, bone density loss, hot flashes, and fatigue. Bone loss is a class-wide concern with aromatase inhibitors. The drugs lower circulating estrogen to near-undetectable levels, removing the protective effect estrogen has on bone.⁸ Most women on either drug will have their bone density monitored, and many end up taking bone-protective medications alongside their aromatase inhibitor.

Joint symptoms are the most common complaint. A retrospective study of 141 patients found that about 60% experienced joint symptoms regardless of which drug they took, with no significant difference in overall frequency or timing.⁹ One interesting distinction did emerge: painless joint symptoms like stiffness appeared significantly more often with anastrozole (about 41%) than with letrozole (about 24%), though actual joint pain did not differ between groups.⁹

A direct comparison of overall quality of life found no significant differences between the two drugs. Nearly 80% of patients reported at least one side effect with either agent, and there were no differences in the frequency, severity, or range of side effects.¹⁰ Their effects on cholesterol and lipid profiles also appear equivalent; a randomized study found no significant differences in lipid metabolism between the two.¹¹

Switching Between the Two

A common real-world scenario is a patient who starts on one aromatase inhibitor and develops intolerable side effects, usually musculoskeletal pain. Since letrozole and anastrozole have slightly different pharmacological profiles and interact with different liver enzymes, switching from one to the other can sometimes allow a patient to continue aromatase inhibitor therapy. The ATOLL study tracked patients who switched from anastrozole to letrozole because of musculoskeletal symptoms. After six months on letrozole, about 72% of them were able to continue treatment.¹² About 29% still had to stop because of severe joint pain, but that means the switch rescued more than two out of three patients who would otherwise have dropped off aromatase inhibitor therapy entirely.

This principle works in both directions. The clinical consensus is that when a patient cannot tolerate one nonsteroidal aromatase inhibitor, the other can serve as an alternative.¹³ In Thailand, for instance, when anastrozole was removed from the national essential drug list, patients were automatically transitioned to letrozole with broadly comparable outcomes. The reason switching works despite the drugs being so similar pharmacologically is not fully understood, but it may relate to individual differences in drug metabolism and receptor sensitivity.

Adherence Over the Long Haul

Aromatase inhibitor therapy typically runs for five years, and sometimes longer. Staying on the medication for the full course matters enormously for outcomes, yet non-adherence is a widespread problem. A study of older women with breast cancer found that overall non-adherence was about 41% and non-persistence (stopping the drug entirely) was about 49%. Among the aromatase inhibitors, anastrozole actually showed the best adherence profile, followed by letrozole, with exemestane performing worst.¹⁴ Tamoxifen, the older hormonal therapy, was associated with the best compliance overall. Patients who were also taking statins or osteoporosis medications tended to stick with their aromatase inhibitor more reliably, which may reflect better overall engagement with their treatment plan rather than any direct drug effect.

The question of extended therapy, going beyond five years, has been tested mainly with letrozole. A trial that extended aromatase inhibitor treatment to 10 years found a five-year disease-free survival rate of 95% with letrozole versus 91% with placebo after the initial course, a significant improvement. The rate of new cancer in the opposite breast was also cut in half. But overall survival was not different, and bone-related side effects increased with longer treatment.¹⁵ Another trial found a more modest benefit, with extended letrozole improving 12-year disease-free survival from 62% to 67%.¹⁶ Yet a third trial found that five years of letrozole after prior aromatase inhibitor therapy did not significantly prolong disease-free survival compared to placebo.¹⁷ The mixed results suggest that extended treatment benefits depend heavily on individual risk factors, and the decision is typically made case by case.

Off-Label Uses in Fertility

Outside of breast cancer, letrozole has become a first-line fertility drug, particularly for women with polycystic ovary syndrome. By temporarily blocking aromatase, letrozole reduces estrogen levels, which tricks the brain’s pituitary gland into releasing more follicle-stimulating hormone, prompting the ovaries to develop and release eggs. A Cochrane review of 11 trials involving over 2,000 participants found that women using letrozole had substantially higher live birth rates than those using clomiphene, the traditional first-line fertility medication. Women with a 20% chance of live birth on clomiphene could expect that chance to rise to somewhere between 27% and 35% with letrozole.¹⁸

A landmark trial in the New England Journal of Medicine confirmed this advantage more precisely: women who received letrozole had a cumulative live birth rate of about 28% versus 19% with clomiphene, and cumulative ovulation rates were about 62% versus 48%.¹⁹ There was no significant difference in overall congenital anomalies between the two groups. Beyond polycystic ovary syndrome, aromatase inhibitors have also been explored for superovulation in patients with unexplained infertility or endometriosis.²⁰

Anastrozole has found its own off-label niche in men. In men who are overweight or obese with low testosterone and an abnormal testosterone-to-estradiol ratio, anastrozole blocks the conversion of testosterone to estradiol, allowing testosterone levels to rise. A study of subfertile men with a body mass index of 25 or higher found that five months of anastrozole treatment nearly doubled testosterone levels (from about 271 to 412 ng/dL) while cutting estradiol roughly in half.²¹ This application takes advantage of anastrozole’s moderate potency; the goal is to shift the hormonal balance without obliterating estrogen entirely, since men need some estrogen for bone health and other functions.

Genetics and Individual Response

Not everyone responds equally to aromatase inhibitors, and researchers have been investigating whether genetic variation in the aromatase gene itself (CYP19A1) might explain why. A polymorphism known as rs4646 in this gene has been linked to differences in treatment response. In one study, patients carrying certain variants of rs4646 had a poorer response to neoadjuvant letrozole, with a greater likelihood of disease progression. The effect was particularly pronounced in elderly patients who did not proceed to surgery after letrozole treatment.²²

Somewhat counterintuitively, a meta-analysis looking at the same polymorphism in women with metastatic breast cancer found that those carrying the rs4646 variant actually had a longer time to disease progression compared to women without the variant.²³ The apparently conflicting findings likely reflect differences in patient populations and disease stages, and the research on pharmacogenomics of aromatase inhibitors remains in an early phase. Only 12 studies made it into that meta-analysis, and they varied widely in which genetic variants they tested and which outcomes they measured. For now, genetic testing does not play a routine role in choosing between letrozole and anastrozole, but it represents a direction that could eventually personalize these decisions.

Cost and Access

Both drugs have been available as generics for years, which has dramatically lowered their cost. Still, small price differences exist depending on the country and insurance system, and these have been analyzed in formal cost-effectiveness studies. One model estimated that starting treatment with letrozole rather than anastrozole added about $3,900 in lifetime costs but produced a small gain in quality-adjusted life years, working out to roughly $25,800 per quality-adjusted year gained.²⁴ That figure is well within what health systems typically consider worthwhile, though the analysis was done when brand-name pricing was still relevant. A German analysis similarly found letrozole to be cost-effective, with the economics becoming increasingly favorable as generic prices dropped.²⁵ In today’s generic market, the out-of-pocket difference between the two is often negligible, and the choice rarely comes down to cost alone.

Aromatase Inhibitors in Male Breast Cancer

Male breast cancer is rare, accounting for less than 1% of all breast cancers, and treatment decisions are largely extrapolated from research in women. A retrospective study of 15 men with metastatic breast cancer treated with aromatase inhibitors (mostly letrozole and anastrozole) found a combined response rate of about 40%, with two complete responses and four partial responses. The median time before the disease progressed was about four and a half months, and the median overall survival was 33 months.²⁶ These results are modest compared with what tamoxifen achieves in men, which is why current guidelines generally favor tamoxifen for male breast cancer and reserve aromatase inhibitors for cases where tamoxifen is not tolerated or not effective. The evidence is thin enough that no head-to-head comparison between letrozole and anastrozole in men exists.

Why the “Better” Drug Doesn’t Always Win

It might seem paradoxical that letrozole is measurably stronger at suppressing estrogen yet produces almost identical clinical outcomes. Several factors likely explain the gap between pharmacology and clinical results. First, both drugs suppress estrogen well past the threshold needed to starve most hormone-sensitive tumors. Think of it like two overpowered engines in vehicles with the same speed limit: the stronger engine does not get you there faster because both are already past what is needed. Second, the side effects that drive patients off therapy are similar for both drugs, so any theoretical potency advantage gets diluted by real-world adherence patterns. Third, breast cancer biology is complicated. Not all recurrences are driven purely by estrogen, and no amount of additional estrogen suppression will prevent a recurrence caused by other molecular pathways.

Where letrozole’s extra potency might matter most is in settings where estrogen suppression is incomplete or marginal, such as in women with higher body mass indices (more fat tissue means more aromatase activity) or in the neoadjuvant setting when the goal is to shrink a tumor before surgery. But even in these scenarios, the clinical data have not consistently shown an advantage. For most patients, the choice between letrozole and anastrozole comes down to individual tolerability, drug interaction profiles, and sometimes just which medication the pharmacy has in stock.